EMD Serono, the biopharmaceutical business of Merck KGaA in the United States and Canada, recently showcased 14 presentations at the 31st Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), including eight sets of data on Cladribine Tablet, a treatment for patients with relapsing multiple sclerosis (MS).
"Our ongoing research underscores the company's commitment to developing new therapeutic options for patients with MS," Dr. Joseph Leveque, chief medical officer at EMD Serono, said in a statement. "Data presented at CMSC add to the body of research evaluating the efficacy and safety of Cladribine Tablets as a potential treatment option for patients with relapsing MS."
The data shows Cladribine reduces annualized relapse rate in patients compared to placebo. The tablets are still being evaluated, and have yet to be approved for treatment in the United States, Canada or Europe.
"We compared the results from two 2-year studies to further understand the duration of efficacy of Cladribine Tablets," Dr. Kottil Rammohan, an investigator in the CLARITY studies at the University of Miami, said. "It's important that we saw similar results replicated in the CLARITY extension trial, which further supports the overall efficacy profile of Cladribine Tablets. Rates of clinical and MRI disease activity-free status were consistent with Cladribine Tablets across all subsets of MS patients for the duration in both trials."